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ABSTRACT
Context: Induction of labour is an old procedure performed to artificially terminate pregnancy for various 
indications in the interest of the mother, the fetus or both. The aim is to achieve vaginal delivery. Various 
methods have been in use which include the use of Misoprostol, Dinoprostone, oxytocin infusion and 
others. In an effort to determine which agent gives better outcome studies were carried out comparing the 
agents with one another.
Objectives: To compare the outcomes of labour induced with Misoprostol and Dinoprostone and to 
determine the incidence of induction of labour at Aminu Kano Teaching Hospital Kano Nigeria.
Materials and Methods:The study was restrospective involving a total of 364 patients admitted for labour 
induction between January 2005 to December 2009. Out of this 274 were induced with Misoprostol and 90 
were induced with Dinoprostone.
Results: The incidence of labour induction is 2.35%. The indications include postdatism, Hypertensive 
disorders of pregnancy, PROM, IUFD and others such as Sickle cell disease, and Diabetes Mellitus. The 
most common indication was postdatism 45.9%. The success rate was 83.9% for Misoprostol and 82.2% for 
Dinoprostone. There is a statistically significant difference in terms of shorter induction delivery interval in 
favour of Misoprostol. There were less number of babies with APGAR score less than 6 in the Misoprostol 
group. There is no statistically significant difference in terms of the spontaneous vaginal deliveries and 
caesarean section rates between the two groups.
Conclusion: The rate of induction of labour in the centre is 2.35%. Misoprostol was found to be a more 
efficient and safer agent for induction of labour if the procedure is well managed. It was associated with 
shorter induction delivery interval without compromising the fetomaternal outcome compared to 
Dinoprostone.




Induction of labour is the termination of 
pregnancy of gestational age 28 weeks or more 
by artificial means with the aim of achieving 
1vaginal delivery .
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Labour induction is among the most frequent 
procedures performed in pregnant women and 
many studies have demonstrated that cervical 
ripeness is one of the most important factors in 
5predicting a successful labour induction
The history of labour induction dates back to 
Hippocrates' original description of mammary 
stimulation and mechanical dilatation of the 
2cervical canal . In 1948 Theobald and 
associates introduced the intravenous 
3administration of oxytocin for labour induction
Karim and colleaques were the first to report the 
2use of prostaglandins for labour induction . 
Prostaglandins are now the focus as important 
mediators and possible initiators of uterine 
8contractions .  Labour induction with 
prostaglandin F2á was introduced in the 1960s 
and subsequently formulations of prostaglandin 
E  (Dinoprostone) were developed which 2
4largely replaced the use of PGF2á . Thus far, 
prostaglandins, particularly PGE, have been 
shown to be the most effective agents in 
5achieving cervical ripening . Dinoprostone has 
been the agent of choice for preinduction 
cervical ripening for several decades and 
currently the only pharmacological agent 
approved by the United States of America Food 
6and Drug Administration for this purpose . The 
most common route of administration is 
vaginal. Tablets, suppositories, gels and 
pessarries have been developed. With the use of 
dinoprostone many patients will require 
oxytocin augmentation which is one of its 
drawbacks. Other drawbacks include 
prolonged induction delivery interval and 
because it is temperature sensitive requires 
continued refrigeration up to the time of use. 
This may not always be possible in developing 
countries like ours. Another important problem 
with its use is affordability as its cost is very 
6  high. A 10 mg vaginal insert costs N6,720
which most patients in deprived areas cannot 
afford.
In an attempt to find an agent with better 
attributes misoprostol was recently introduced. 
It is an orally active prostaglandin E1 analogue 
originally used for the treatment of peptic ulcer. 
It has entered clinical use in obstetrics and 
gynecology on a wide scale without having been 
7registered for such use . It has no significant 
8vasoactivity in humans . It is cheap, a 200 
microgram tablet costs about N150 and can be 
6afforded by many patients . It is active by oral, 
vaginal and rectal routes for induction of 
9,10labour . It can be stored at room temperature 
11,12with shelf life of several years . Its safety has 
been established by several pharmacological 
studies and extensive experience in its use as an 
13anti-ulcer drug . It ripens the cervix and also 
enhances uterine contractions, thereby reducing 
14the need for oxytocin . These factors  make 
misoprostol very attractive as an agent for labour 
induction.
Because dinoprostone (PGE2) is widely 
recognized and accepted as a standard method of 
labour induction, alternative methods which are 
less well established are compared with it as the 
4gold standard . In an effort to determine  which 
agent or method of induction has minimal 
fetomaternal side effects, gives the best possible 
fetomaternal outcome and can be monitored, 
various studies were conducted. The efficiency 
of oxytocin for induction of labour has been 
1studied . Other studies evaluated misoprostol for 
6,8,15induction of labour . Some studies were 
comparing the various agents against one 
another with a view of determining which is one 
more efficacious. Such studies include that 
16,17,18comparing Misoprostol Vs oxytocin , 
19,20,21,22,23Misoprostol Vs dinoprostone ,Foley's 
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catheter plus titrated oral misoprostol solution, 
t i t rated oral  misoprostol  a lone and 
24dinoprostone , as well as misoprostol and 
6placebo . Induction of labour has been an 
important obstetrical procedure because its 
application has implication for both the mother 
and the fetus. A good outcome is always what 
the obstetrician aspires to achieve and the 
mother will wish to have. 
It is for this reason that studies must continue 
comparing agents and methods that will give 
the best possible fetomaternal outcome. It is in 
the light of this that this study was conducted.  
The study is aimed at comparing the outcome of 
labour induction with Misoprostol and 
dinoprostone  and to determine the incidence of 
induction of labour at AKTH.
MATERIALS & METHOD
The study was retrospective comparing the 
outcome of labour induction with Misoprostol 
and Dinoprostone. 
 It was carried out at the Obstetrics and 
Gynaecology Department of Aminu Kano 
Teaching Hospital Kano, between January 2005 
to December 2009. The study population 
consisted of all women admitted for induction 
of labour within the study period. Case records 
of patients were obtained from the Records 
Department with supplementation from 
antenatal and labour ward reords.
Misoprostol and Dinoprostone were routinely 
used for induction of labour within the study 
period. The dose of Misoprostol used was 50 
microgram except for high parity patients in 
whom 25 microgram was used. A 200 
microgram of Misoprostol is broken in to 
approximately four equal parts. With the patient 
in dorsal position a piece 50 microgram is 
inserted into the posterior fornix with the 
gloved right hand while parting the labia with 
the gloved left hand. This is done six hourly for a 
maximum of 4 doses until labour begins. The 
Bishop score is assessed before the first insertion 
and before each subsequent insertion. The dose 
of Dinoprostone used was 1.5 mg which is 
inserted into the posterior fornix six hourly for a 
maximum of 3 doses.
Sociodemograhic data recorded include age and 
parity of patients, pre-induction Bishop scores, 
weights and heights of patients, birth weights of 
babies delivered, induction delivery intervals, 
APGAR scores of babies, mode of delivery and 
indication for induction. Data was analysed 
using Epi-Info software version 3.4.1, July 3 
2007. The results were given in percentages and 
tables and bar chart were used to display the 
data. Chi square and z test where used to test for 
significance at 95% confidence interval.
RESULTS
Table 1:  Demographic characteristics of 














Age 20-24 68 24.8 22 24.4













































3 26 9.5 8 8.9
4 16 5.8 6 6.7
5+ 72 26.3 24 26.6
Total 274 100.0 90 100.0
figure 1: Indications for induction of labour.
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DISCUSSION
The rate of induction of labour in our centre is 
2.35% of all deliveries. Which is lower than 
153.0% that was reported from Sokoto , and lower 
25than 5% reported from South Africa . It is lower 
26than 23% reported from developed countries . 
The indications for induction of labour from this 
study are similar to those reported from Sokoto 
15North West Nigeria . 
The overall success rate for labour induction in 
this study was 83.5% which is similar to 82% 
15reported from Sokoto . It is however lower than 
90.40% reported from Benin South South 
1Nigeria . The reason for this difference may be 
due to the fact that in the Benin study induction 
was restricted to women carrying term 
pregnancies, while some patients were not at 
term in our study.
The two groups of patients in the study share 
similar characteristics such, mean Bishop score 
at induction, mean maternal height and mean 
birthweight of babies delivered. There is no 
statistically significant difference in these 
parameters (table 5).These provide a valid basis 
for comparison and thus eliminates bias. The 
similarities in the two groups is probably 
because they are from the same community.
This study revealed that there was no 
statistically significant difference in the number 
of spontaneous vaginal deliveries or caesarean 
section rates between the two groups (table2). 
27,6,28Studies elsewhere gave similar results . This 
result is however in variance with what was 
29,22reported by workers elsewhere  in which the 
caesarean section rate was found to be higher. 
The difference in caesarean section rate in the 
two studies were attributed to the greater 
number of caesarean sections done on account 
of fetal distress in the Misoprostol group. The 
difference is probably due to the difference in 
Table 2: Mode of delivery:




   
Dinoprostone 16(17.8%) 74(82.2%) 0.8276634  0.88  0.45-1.74
Total 60(16.5%) 304(83.5%)
Table 3: Apgar Score:




   
Dinoprostone 22(24.4%) 68(75.6%)  0.0002133  0.30 0.15-0.59
Total 46(12.6%) 318(87.4%)
Table 4: Induction delivery Interval 
(IDI):




   




   
Misoprostol Dinoprostol









1.6±0.05m 1.5±0.07m  Z=0.52 p>0.05







Table 5: Mean bith weight of babies 
delivered, Mean maternal height, and Mean 
Bishop score at induction.    
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Misoprostol protocol, where they used 25 
micrograms while we used 50 micrograms for 
most patients except those with high parity were 
25 micrograms was used.
This study showed that the induction delivery 
interval was shorter and delivery within 12 hrs 
was much higher in the Misoprostol group 
(table4). Other studies reported similar 
27,29findings . Misoprostol being  more efficient 
as a cervical ripening agent as well as an inducer 
of labour is likely to give a shorter induction 
1delivery interval compared to Dinoprostone . It 
may also be that because of its low cost 
Misoprostol is used more often compared to 
Dinoprostone which is more costly  and  many 
patients cannot afford it.
Newborn  APGAR score of less than 6 was 
statistically significantly higher among the 
Dinoprostone group (table3).The difference 
may be attributed to the longer induction 
delivery interval (IDI) in the Dinoprostone 
group which means that babies in this group 
were subjected to more stress of labour and 
hence were more prone to fetal distress and 
lower APGAR score at delivery. Since the mean 
Bishop's score at induction was not statistically 
different in the two groups (table5 ) it may not 
be the factor that led to the finding of more 
babies with APGAR scores less than 6 in the 
Dinoprostone group and also more patients 
with IDI less than 12hrs in the same group. 
Other studies have however not shown a 
statistically significant difference in APGAR 
29score less than 6 , probably because in their 
study uterine hyperstimulation were more in the 
Misoprostol group, and also probably because 
of the difference in the protocol of management 
of use of Misoprostol for induction of labour.
CONCLUSION The rate of induction of labour 
in our centre is 2.35%. Misoprostol was found to 
be a more efficient and safer agent for induction 
of labour if the procedure is well managed. It is 
associated with shorter induction delivery 
interval without compromising the fetomaternal 
outcome compared to Dinoprostone. Based on 
these findings it will appear that Misoprostol is a 
better choice when induction of labour is being 
considered. The study was retrospective and is 
therefore limited by factors that affect the quality 
of retrospective studies. To confirm or dispute 
the findings of this study well designed 
prospective studies will be needed.
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